




Progression-free survival probability  $\pm 95\%$  credible intervals



- |                          |                             |   |  |
|--------------------------|-----------------------------|---|--|
| Lapatinib + capecitabine | Margetuximab + capecitabine | Pertuzumab + trastuzumab + capecitabine | Tucatinib + trastuzumab + capecitabine |
| Capecitabine             | Neratinib                   | T-DM1                                   | Vinorelbine                            |
| Eribulin                 | Neratinib + capecitabine    | Trastuzumab + capecitabine              |  |



Overall survival probability  $\pm 95\%$  credible intervals



- Lapatinib + capecitabine
- Eribulin
- Neratinib + capecitabine
- T-DM1
- Tucatinib + trastuzumab + capecitabine
- Capecitabine
- Neratinib
- Pertuzumab + trastuzumab + capecitabine
- Trastuzumab + capecitabine
- Vinorelbine

